Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | POLQ | O75417 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217764 | 0.92 | HPGDS (0.54) | HPGDSCSNK1DMAP4K4DGAT1POLQ | |
| SCHEMBL3810374 | 0.89 | HPGDS (0.51) | HPGDSCSNK1DMAP4K4DGAT1POLQ | |
| SCHEMBL2471757 | 0.89 | HPGDS (0.54) | HPGDSCSNK1DMAP4K4DGAT1ATR | |
| SCHEMBL14041378 | 0.88 | HPGDS (0.51) | HPGDSCSNK1DMAP4K4DGAT1POLQ | |
| SCHEMBL12083923 | 0.87 | HPGDS (0.54) | HPGDSCSNK1DDGAT1 | |
| SCHEMBL12083724 | 0.87 | HPGDS (0.50) | HPGDSCSNK1DEPHX2PPARGPOLQ | |
| SCHEMBL12084048 | 0.86 | HPGDS (0.49) | HPGDSCSNK1DMAP4K4DGAT1ALOX5AP | |
| SCHEMBL12084161 | 0.86 | HPGDS (0.49) | HPGDSCSNK1D | |
| SCHEMBL12083978 | 0.85 | HPGDS (0.49) | HPGDSMAP4K4DGAT1 | |
| SCHEMBL3717427 | 0.84 | HPGDS (0.51) | HPGDSCSNK1DMAP4K4DGAT1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885CSNK1D 1144/4885MAP4K4 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.